Did You Know? The Importance of HRD Testing in Advanced Ovarian Cancer With Maurie Markman, MD Just like normal cells, cancer cells have ways of repairing damage that occurs to them. In this episode of Science Illustrated we Experts in gynecologic oncology discuss the potential for bevacizumab or olaparib monotherapy as frontline therapy in ovarian
Testing for BRCA and HRD in Ovarian Cancer Introduction to Homologous Recombination Deficiency (HRD) assessment
Dr Kaklamani talks to ecancertv at SABCS 2015 about a pooled analysis of five phase II studies showing that homologous Panelists Robert L. Coleman, MD; Gottfried E. Konecny, MD; Bradley J. Monk, MD; Katie Moore, MD; and Matthew A. Powell, MD, Multiomic analysis of homologous recombination-deficient end
Homologous recombination repair (HRR) gene mutations result in homologous recombination deficiency (HRD) associated with Alicia's story: What genetic mutations do you have? When and how were you tested? The panel further evaluates the role of homologous recombination deficiency in ovarian cancer and when it is appropriate to test
Testing HRD in the clinic Antonio González-Martín, MD, University of Navarra, Pamplona, Spain, highlights the challenges faced by patients with Episode 3: HRD What? HRD Why?
HRD Testing in Ovarian Cancer Evaluating the interchangeability of HRD testing in ovarian cancer
The influence of HRD testing in precision medicine Ovarian Cancer: What is the Role of HRD Testing?
Where is ovarian cancer treatment headed? Leading gynecologic oncologists Dr John Nakayama, Dr Joshua Kesterson, and Dr Alex Olawaiye review what it means to test for
30 Years of Genetics: Understanding BRCA and HRD in ovarian cancer What are the different characteristics of homologous recombination deficiency (HRD) tests?
Dr Maurie Markman discusses the importance of HRD testing in advanced ovarian cancer, using the Myriad MyChoice® Panelists Adam M. Brufsky, MD, PhD; Mark E. Robson, MD; Kimberly L. Blackwell, MD; and Aditya Bardia, MD, MPH, provide Dr Heeke speaks with ecancer at ASCO 2017 about the prevalence of haematology recombination deficiency among 53000
Homologous Recombination Deficiency in Ovarian Cancer: from the Treating Ovarian Cancer Based on HRD Status What is HRD (Homologous Recombination Deficiency) and how does it impact ovarian cancer?
Beyond BRCA and HRD Impact of HRD Status on Frontline Treatment of Ovarian Cancer Treating Homologous Recombination Proficient Ovarian Cancer
Dr. Coleman, Chief Scientific Officer, US Oncology Network, explains the underlying biology of homologous recombination Find out more about what homologous recombination deficiency (HRD) means, how you have genetic testing for it and what your Watch Dr ElNaggar discuss the clinical utility of homologous recombination deficiency (HRD) and how testing for HRD at
Watch this event back to have your questions about HRD and genetics answered by Dr Alexandra Murray, Consultant Clinical High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and,
Homologous recombination DNA-repair deficiency (HRD) is a common driver of genomic instability and confers a therapeutic vulnerability in HRD Testing in Ovarian Cancer - What Do You Need to Consider?
In this review, we discuss the epidemiology and management of homologous recombination deficiency in ovarian cancer patients. Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and Benoit You, MD, PhD, Lyon University Hospital, Lyon, France, comments on whether the various tests for homologous
Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4- Bradley J. Monk, MD, FACOG, FACS, reacts to advances in molecular testing used to identify predictive biomarkers to guide In this webinar, we'll explore Homologous Recombination Deficiency (HRD) testing, addressing questions like who should have
Webinar on Significance of HRR gene testing in Prostate and Ovarian Cancer Matthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of
Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian Cancer Joseph Dottino, MD, MPH, a gynecologic oncologist at BIDMC, discusses hereditary ovarian cancer, who should be tested and
Overcoming treatment challenges in HRD negative ovarian cancer BRCA1/2 Status and Homologous Repair Deficiency in TNBC
In this webinar, the Ovacome team are joined by Dr Rowan Miller, Consultant Medical Oncologist specialising in gynae-oncology Is HRD Testing Recommended for All Individuals at Risk of Ovarian Cancer? In this informative video, we'll discuss the role of
The discovery that PARP inhibitors block an essential pathway of DNA repair in cells harbouring a BRCA mutation has opened up a new therapeutic avenue for high Dr. Rana on Genetic Testing Guidelines for Patients With Ovarian Cancer Hereditary Ovarian Cancer – BRCA and Beyond
Homologous Recombination Deficiency | Central Principles of Molecular Biology Next-Generation Sequencing (NGS) Assessment of Homologous Recombination Deficiency (HRD)
Homologous Recombination Deficiency: Exploiting the Fundamental Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses the importance of Featuring perspectives from Dr Bradley J Monk, including the following topics: • Introduction (0:00) • Case: A woman (gBRCA1) in
Optimized detection of homologous recombination deficiency Jerry Lanchbury, PhD, Describes Myriad's HRD Test
Homologous recombination deficiency (HRD) and comprehensive genomic profiling (CGP) Homologous recombination deficiency HRD testing for ovarian cancer
Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, Homologous Recombination Deficiency (HRD) in Tumors presented by Dr. Maher Albitar ACT Genomics Dinner Symposium | Moving from BRCA1/2 to HRD: Beyond Woman's Cancers
"What are your thoughts on HRD testing in ovarian cancer if negative for BRCA?" Stefan Gysler, MD, MHS, Assistant Clinical Leslie Randall, MD, FACOG, defines homologous recombination deficiency and the use of the Myriad myChoice scoring system The Role of Molecular Testing in Advanced Ovarian Cancer
As the field of precision medicine evolves, novel biomarkers are emerging and established ones are being tested outside their This is an in-depth review of how HRD testing is performed, the differences between HRR and HRD. It also discusses the genes Illumina Oncology - Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer
Presented By: Dr. Christopher Lum, M.D. Zan Halford, M.S. SMB(ASCP)CM, Speaker Biography: Medical Director of the Precision Considerations for how a patient's homologous recombination deficiency status informs treatment decisions in ovarian cancer.
In this video, Dr. Nicola Normanno (National Cancer Institute Pascale Foundation, Naples Italy) explains how the institute became What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated HRD in ovarian cancer: defined today, evolving for the future
The virtual roundtable panelists brought expertise and perspectives on genetic testing for ovarian cancer and discuss ways to we ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander
We will look at the discovery of BRCA1 and BRCA2 gene mutations, and how genetic testing became a key part of ovarian cancer As with PD-L1, HER2, and EGFR, an understanding of a patient's HRD status is a critical component of personalized cancer care.
Homologous recombination deficiency (HRD) is when cells are unable to repair breaks in their DNA using homologous recombination. This is because the homologous Options With Genetic Testing in Ovarian Cancer The importance of HRD testing in ovarian cancer
Homologous recombination deficiency in ovarian cancer: a review of Is HRD Testing Recommended for All Individuals at Risk of Ovarian Cancer? Ask the Experts: HRD and Genetics
BRCA across tumour types Benoit You, MD, PhD, Lyon University Hospital, Lyon, France, discusses how homologous recombination deficiency (HRD) testing Homologous recombination repair (HRR) is an important mechanism for DNA double-strand damage repair. The BRCA genes
In this video, Judith Balmaña addresses the role of the BRCA1 and BRCA2 proteins in cancer risk assessment, early detection Homologous recombination deficiency predicts neo-adjuvant chemotherapy response
This review describes the technical aspects and challenges related to HRD testing in ovarian cancer and outlines the potential pitfalls and challenges Somatic Mutation Testing for Ovarian Cancer
Homologous recombination deficiency and ovarian cancer Homologous recombination deficiency | Target Ovarian Cancer
Dr. Nicola Normanno (National Cancer Institute Pascale Foundation, Naples Italy) explains the clinical need to assess The landscape of ovarian cancer treatment is rapidly changing, with PARP inhibitors moving into the first-line setting and new Virtual Patient Perspectives Roundtable: Overcoming Barriers to Genetic Testing in Ovarian Cancer
Review Homologous recombination deficiency and ovarian cancer Angeles Alvarez Secord, MD, talks with her patient, Michelle Berke, about genetic testing in ovarian cancer. Isabelle Ray-Coquard, MD, PhD, of the Léon Bérard Center and the Claude Bernard University Lyon 1, Lyon, France, discusses
Learn more about ovarian cancer at Alicia talks about the experiences she had with Homologous Recombination Deficiency and Cancer Care Robert Coleman, MD, FACOG, explains the underlying biology of homologous recombination deficiency
Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic Broken DNA, erroneously repaired DNA and scarred DNA, can all be the genetic consequences of Homologous Recombination Dr. Poveda, Medical Coordinator, Quirónsalud Hospital, discusses how the BRCA mutation and homologous recombination
Prevalence of homologous recombination deficiency among 53,000 tumour samples Andres Poveda, MD, discusses the BRCA mutation and homologous recombination deficiency This educational video explores main concepts of homologous recombination deficiency (HRD) and different testing approaches.
The inability to efficiently repair DNA double-strand breaks using the homologous recombination repair pathway is defined as homologous Ovarian cancer treatment continues to evolve and some women benefit from new therapy options in addition to gold standard